Literature DB >> 16047477

Effect of concomitant polyethylene glycol and celecoxib on colonic aberrant crypt foci and tumors in F344 rats.

Khoa Do1, Graham F Barnard.   

Abstract

We investigated whether celecoxib augments the protective effect of polyethylene glycol (PEG) on colonic aberrant crypt foci (ACF) and tumor formation in F344 rats treated with azoxymethane (AOM). Three groups of rats received AOM: I (AOM alone), II (PEG), and III (PEG/celecoxib). PEG reduced the mean number of total ACF per colon from 190 to 141 (P < 0.05; 26% reduction) and > or = 4-crypt ACF from 95 to 58 (P < 0.01; 39%). Group III rats had a greater proportion of their ACF distally; whereas transverse colon ACF were reduced approximately 50%, distal ACF were reduced by only approximately 8% (P < 0.05). Of 13 large bowel tumors, 8 were in Group I, 4 in Group II, and 1 in Group III rats (P = 0.02). Thus in AOM-treated rats celecoxib appeared to enhance the PEG-induced reduction in colonic tumor formation, and in transverse but not distal or whole-colon ACF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047477     DOI: 10.1007/s10620-005-2777-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Authors:  W A Bleeker; V M Hayes; A Karrenbeld; R M Hofstra; J Hermans; C C Buys; J T Plukker
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

2.  Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation.

Authors:  A Attar; M Lémann; A Ferguson; M Halphen; M C Boutron; B Flourié; E Alix; M Salmeron; F Guillemot; S Chaussade; A M Ménard; J Moreau; G Naudin; M Barthet
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

3.  Polyethylene glycol 8000 and colon carcinogenesis: inhibition in the F344 rat, promotion in the Min mouse.

Authors:  D Naigamwalla; M C Chia; T T Tran; A Medline; K Hay; S Gallinger; W R Bruce
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Aberrant crypt foci in human colons: distribution and histomorphologic characteristics.

Authors:  B Shpitz; Y Bomstein; Y Mekori; R Cohen; Z Kaufman; D Neufeld; M Galkin; J Bernheim
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

5.  Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.

Authors:  U Ladabaum; C L Chopra; G Huang; J M Scheiman; M E Chernew; A M Fendrick
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

6.  Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

Authors:  B S Reddy; Y Hirose; R Lubet; V Steele; G Kelloff; S Paulson; K Seibert; C V Rao
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas.

Authors:  R S Sandler; J C Galanko; S C Murray; J F Helm; J T Woosley
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

8.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Authors:  T Kawamori; C V Rao; K Seibert; B S Reddy
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

9.  Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate.

Authors:  T P Pretlow; M A O'Riordan; G A Somich; S B Amini; T G Pretlow
Journal:  Carcinogenesis       Date:  1992-09       Impact factor: 4.944

10.  Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease.

Authors:  H Bouzourene; P Chaubert; W Seelentag; F T Bosman; E Saraga
Journal:  Hum Pathol       Date:  1999-01       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.